Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC

BACKGROUND: Patients treated with immunotherapy are at risk of considerable adverse events, and the ongoing struggle is to accurately identify the subset of patients who will benefit. Tumor mutational burden (TMB) has emerged as a promising predictive biomarker but requires tumor tissue which is not...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuurbiers, Milou, Huang, Zhongyun, Saelee, Senglor, Javey, Manana, de Visser, Leonie, van den Broek, Daan, van den Heuvel, Michel, Lovejoy, Alexander F, Monkhorst, Kim, Klass, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883268/
https://www.ncbi.nlm.nih.gov/pubmed/35217576
http://dx.doi.org/10.1136/jitc-2021-004064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883268/
https://www.ncbi.nlm.nih.gov/pubmed/35217576
http://dx.doi.org/10.1136/jitc-2021-004064

Ejemplares similares